S-033188 is the world's first inhibitor against influenza virus with cap-like structure (CAP) -dependent endonuclease activity. The results showed that the symptom relief time (TTAS) was significantly reduced compared with placebo, and other important secondary clinical end points (such as reduced virus titer) also achieved positive results. Preclinical study data for A / H7N9 (avian influenza) were also presented.
Source: Shionogi news release, September 17, 2017
Request a quote for deeper information from